Gaucher disease: Recent advances in the diagnosis and management. | ||||
| Medical Journal of Viral Hepatitis | ||||
| Article 3, Volume 6.2, Issue 2, April 2022, Page 6-10 PDF (176.18 K) | ||||
| Document Type: Review articles | ||||
| DOI: 10.21608/mjvh.2022.234477 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Fetouh Hassanin   1; Azza Hasan Abbas2; Mona Schalaan3; Mohamed Rabea 4
| ||||
| 1Pediatrics, Misr International University, Cairo, Egypt | ||||
| 2Medical Parasitology, Immunology and Microbiology Department, National Hepatology and Tropical Medicine Research Institute (NHTMI), Cairo, Egypt | ||||
| 3Clinical Pharmacy department (Biochemistry), Misr International University, Cairo, Egypt. | ||||
| 4Department of Pediatric Gastroenterology, National Hepatology and Tropical Medicine Research Institute (NHTMI), Cairo, Egypt. | ||||
| Abstract | ||||
| Gaucher disease is a rare genetic disorder characterized by the deposition of glucocerebroside in cells of the macrophage-monocyte system. Gaucher disease is an inborn error of metabolism that affects the recycling of cellular glycolipids. This disease is a consequence of deficiency of the enzyme glucocerebrosidase. It causes bone pain, anemia, enlarged organs, painful belly and bruising and bleeding problems. There are many types of Gaucher disease, all cause similar symptoms in the organs and bones. Some forms of the disease also affect the brain. There is no cure for Gaucher disease, but a variety of treatments can help control symptoms, prevent irreversible damage and improve quality of life. Enzyme replacement therapy is the primary form of treatment for Gaucher disease. | ||||
| Keywords | ||||
| Gaucher disease; glucocerebrosidase; Enzyme replacement therapy and hepatosplenomegaly | ||||
|
Statistics Article View: 447 PDF Download: 1,669 |
||||
